| Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes B Zinman, C Wanner, JM Lachin, D Fitchett, E Bluhmki, S Hantel, ... New england journal of medicine 373 (22), 2117-2128, 2015 | 12135 | 2015 |
| Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... Diabetologia 55 (6), 1577-1596, 2012 | 6694 | 2012 |
| Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) MJ Davies, DA D’Alessio, J Fradkin, WN Kernan, C Mathieu, G Mingrone, ... Diabetes care 41 (12), 2669-2701, 2018 | 4096 | 2018 |
| Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... Diabetes care 38 (1), 140-149, 2015 | 3630 | 2015 |
| 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study … JB Buse, DJ Wexler, A Tsapas, P Rossing, G Mingrone, C Mathieu, ... Diabetes care 43 (2), 487-493, 2020 | 1767 | 2020 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1331 | 2018 |
| Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis D Vasilakou, T Karagiannis, E Athanasiadou, M Mainou, A Liakos, ... Annals of internal medicine 159 (4), 262-274, 2013 | 1127 | 2013 |
| Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... Diabetologia 58 (3), 429-442, 2015 | 904 | 2015 |
| American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... Diabetes care 35 (6), 1364-1379, 2012 | 836 | 2012 |
| Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) MJ Davies, VR Aroda, BS Collins, RA Gabbay, J Green, NM Maruthur, ... Diabetes care 45 (11), 2753-2786, 2022 | 637 | 2022 |
| Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis T Karagiannis, P Paschos, K Paletas, DR Matthews, A Tsapas Bmj 344, 2012 | 580 | 2012 |
| Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis E Bekiari, K Kitsios, H Thabit, M Tauschmann, E Athanasiadou, ... bmj 361, 2018 | 433 | 2018 |
| Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) MJ Davies, VR Aroda, BS Collins, RA Gabbay, J Green, NM Maruthur, ... Diabetologia 65 (12), 1925-1966, 2022 | 407 | 2022 |
| The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related … VG Athyros, TK Alexandrides, H Bilianou, E Cholongitas, M Doumas, ... Metabolism 71, 17-32, 2017 | 283 | 2017 |
| Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis A Tsapas, I Avgerinos, T Karagiannis, K Malandris, A Manolopoulos, ... Annals of internal medicine 173 (4), 278-286, 2020 | 256 | 2020 |
| Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, ... Diabetes, Obesity and Metabolism 16 (10), 984-993, 2014 | 251 | 2014 |
| Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms KI Bougioukas, A Liakos, A Tsapas, E Ntzani, AB Haidich Journal of clinical epidemiology 93, 9-24, 2018 | 221 | 2018 |
| Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis ML Griebeler, OL Morey-Vargas, JP Brito, A Tsapas, Z Wang, ... Annals of internal medicine 161 (9), 639-649, 2014 | 214 | 2014 |
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. PA Sarafidis, A Tsapas J Med 373, 2117-2128, 2015 | 207 | 2015 |
| A systematic review and meta-analysis of tests to predict wound healing in diabetic foot Z Wang, R Hasan, B Firwana, T Elraiyah, A Tsapas, L Prokop, JL Mills Sr, ... Journal of vascular surgery 63 (2), 29S-36S. e2, 2016 | 166 | 2016 |
David R MatthewsProfessor of Diabetes, University of OxfordVerified email at ocdem.ox.ac.uk
